

Pnemototoxicity Associated With Rheumatological Drugs (PASSWRD) Tier 1

An e-Delphi exercise to reach consensus on risk of drug-induced pneumotoxicity in patients with rheumatological disease

Section 1

Tier 1

About you. All responses are anonymous.

1. Please enter the email address that this invitation was sent to: (for subsequent engagements if you would prefer to use a different email please contact

loth.delphipneumotoxicity@nhslothian.scot.nhs.uk)

Enter your answer

2. What is your primary specialty?

Rheumatology

Pulmonology

3. Years of experience in your specialty (in years)

1-4

5-9

10-20

> 20

4. How confident do you feel about assessing risk of pneumotoxicity in adults with DMARDS/Biologics and underlying rheumatological conditions?

1= no confidence.

7= extremely confident.

1

2

3

4

5

6

7

5. PATIENT FACTOR DOMAINS

We would like to compile a list of relevant patient factors for Tier 2 of this Delphi exercise.

Which of the following patient factors do you consider when assessing risk of developing pneumotoxicity?

Age

Yes

No

Don't know

6. Gender

Yes

No

Don't know

7. Ethnicity

Yes No Don't know

8. Smoking

Yes No Don't know

9. BMI

Yes No Don't know

10. Underlying rheumatological diagnosis

Yes No Don't know

11. Activity of underlying rheumatic disease

Yes No Don't know

12. If answered "no" or "I don't know" to Q11, please go to Q13. If answered "yes" please specify which measure of activity you consider when assessing risk of pneumotoxicity (tick all that apply)

Disease activity score (e.g. DAS28, BASDAI, PsARC, SLEDAI or other)

Imaging score (MRI, US etc) ESR CRP Ferritin

Complement Autoimmune serological titre (RhF, CCP, Jo-1 etc) Serum ACE

13. Pre-existing interstitial lung disease (ILD)

Yes No Don't know

14. If you responded "no" or "I don't know" to Q13, please go to Q20. If you responded "yes", please indicate which features on HRCT you consider when assessing risk of pneumotoxicity

Pattern of disease (for example UIP, NSIP, etc.)

Yes No Don't know

15. Presence of fibrosis (honeycombing, traction bronchiectasis)

Yes No Don't know

16. Presence of 'inflammation' (ground glass or air-space opacification)

Yes No Don't know

17. Presence of lung nodules

Yes No Don't know

18. Volume of lung affected by ILD on HRCT

Yes No Don't know

19. Progression of ILD between serial HRCT scans

Yes No Don't know

20. COPD and/or emphysema

Yes No Don't know

21. Asthma

Yes No Don't know

22. Bronchiectasis

Yes No Don't know

23. Other respiratory co-morbidities - please specify

Enter your answer

24. Static Lung function measurements (spirometry, gas transfer)

Yes No Don't know

25. If you responded "no" or "don't know" to Q24, please go to Q30. If you responded "yes", please indicate which features on static lung function would you consider when assessing risk of pneumotoxicity

FEV1

Yes No Don't know

26. FVC

Yes No Don't know

27. FEV1/FVC ratio

Yes No Don't know

28. TLCO

Yes No Don't know

29. KCO (=TLCO corrected for alveolar volume)

Yes No Don't know

30. Change in static lung function between historical serial measurements (if available)

Yes No Don't know

31. If answered "no" or "don't know" to Q30, please go to Q35. If answered "yes", please indicate which features of serial static lung function measurement (if available) do you consider when assessing risk of pneumotoxicity.

Change in FEV1

Yes No Don't know

32. Change in FVC

Yes No Don't know

33. Change in TLCO

Yes No Don't know

34. Change in KCO

Yes No I don't know

35. Desaturation on formal exercise testing (e.g. 6MWT, shuttle etc)

Yes No Don't know

36. Walking distance on formal exercise testing (e.g. 6MWT, shuttle etc)

Yes No Don't know

37. Please indicate which non-respiratory co-morbidities you consider when assessing the risk of pneumotoxicity (tick all that apply)

Cardiac Liver GI tract Renal
Neurological Diabetes mellitus Metabolic/endocrine
Haematological Psychiatric None of the above

38. DRUG FACTOR DOMAINS

We would like to compile a list of relevant rheumatological drugs for Tier 2 of this Delphi exercise.

Please identify which drugs you consider to be significantly associated with pneumotoxicity. Consider 'significantly' to be such that you would actively counsel the patient that there is a risk of pneumotoxicity.

Conventional DMARDs (tick all that apply)

Azathioprine Methotrexate Leflunomide Sulfasalazine
Hydroxychloroquine MMF None of the above

39. Anti-TNF (tick all that apply)

Adalimumab Certolizumab Etanercept
Golimumab Infliximab None of the above

40. Do you consider that individual drugs within the anti-TNF class have different risks of pneumotoxicity?

Yes No Don't know

41. Anti-IL1 (tick all that apply)

Anakinra Canakinumab None of the above

42. Do you consider that individual drugs within the anti-IL1 class have different risks of pneumotoxicity?

Yes No Don't know

43. Anti-IL6, (tick all that apply)

Sarilumab Tocilizumab None of the above

44. Do you consider that individual drugs within the anti-IL6 class have different risks of pneumotoxicity?

Yes No Don't know or not applicable

45. Anti IL12/23

Ustekinumab None of the above

46. Do you consider that individual drugs within the anti-IL12/23 class have different risks of pneumotoxicity?

Yes No Don't know or not applicable

47. Anti-IL17 (tick all that apply)

Ixekizumab Secukinumab None of the above

48. Do you consider that individual drugs within the anti-IL17 class have different risks of pneumotoxicity?

Yes No Don't know or not applicable

49. JAK-STAT inhibitors (tick all that apply)

Baricitinib Tofacitinib Upadacitinib

Filgotinib None of the above

50. Do you consider that individual drugs within the JAK-STAT inhibitor class have different risks of pneumotoxicity?

Yes No Don't know or not applicable

51. T-cell modulator

Abatacept None of the above

52. B-cell depleter or modulator (tick all that apply)

Belimumab Rituximab None of the above

53. Do you consider that individual drugs within the B-cell deplete/modulator class have different risks of pneumotoxicity?

Yes

No

Don't know or not applicable

54. Other drugs. In the free text box please indicate any other licensed drugs that you currently use in CTD and you associate with pneumotoxicity